<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41212">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02569879</url>
  </required_header>
  <id_info>
    <org_study_id>201521</org_study_id>
    <nct_id>NCT02569879</nct_id>
  </id_info>
  <brief_title>Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.</brief_title>
  <official_title>Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study is being conducted to assess impact of maternal immunisation against pertussis in
      infants ≤12 months of age before and after introduction of pertussis maternal immunisation
      in Bogota, Colombia from January 2005-December 2014.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An observational, retrospective, ecological database study which involves systematic
      screening of the national databases of Bogota, to study pertussis related morbidity and
      mortality in infants ≤ 12 months of age before and after introduction of pertussis maternal
      immunisation in Bogota, Colombia from January 2005-December 2014.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of reported cases of hospitalisations and deaths due to pertussis in infants ≤6 weeks of age, in post-vaccination period compared to pre-vaccination period of Boostrix vaccination</measure>
    <time_frame>During the 9-year period (January 2005- December 2014)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of reported cases of hospitalisations and deaths due to pertussis in infants 7 weeks to ≤12 months of age, in post-vaccination period compared to pre-vaccination period of Boostrix vaccination</measure>
    <time_frame>During the 9-year period (January 2005- December 2014)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of ALRTI in infants ≤6 weeks of age and 7 weeks to ≤12 months of age, following the introduction of pertussis maternal immunisation in Bogota, Colombia</measure>
    <time_frame>During the 9-year period (January 2005- December 2014)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the total number of doses of Boostrix administered in pregnant women, after its introduction into the UMV program in Bogota</measure>
    <time_frame>During the 9-year period (January 2005- December 2014)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the total number of doses of primary pertussis vaccine administered to infants ≤12 months of age in Bogota</measure>
    <time_frame>During the 9-year period (January 2005- December 2014)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Diphtheria</condition>
  <condition>Acellular Pertussis</condition>
  <condition>Tetanus</condition>
  <arm_group>
    <arm_group_label>Infants Group</arm_group_label>
    <description>All infants ≤12 months of age in Bogota, reported with pertussis disease in the national databases of Bogota, between January 2005 and December 2014.
All infants ≤12 months of age in Bogota, deceased between January 2005 and December 2014 due to pertussis disease (primary diagnosis), based on death certificate information.
All infants ≤12 months of age in Bogota, with ALRTI, between January 2005 and December 2014.
All infants ≤12 months who have received primary pertussis vaccination in Bogota, between January 2005 and December 2014.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnant women Group</arm_group_label>
    <description>• Pregnant women will be included in the study to assess the vaccination coverage of Boostrix from March 2013 to December 2014</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pertussis maternal immunization</intervention_name>
    <description>Retrospective time trend analysis before and after pertussis maternal immunization in Bogota, Colombia.</description>
    <arm_group_label>Pregnant women Group</arm_group_label>
    <arm_group_label>Infants Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  All infants ≤12 months of age in Bogota, reported with pertussis disease in the
             national databases of Bogota, between January 2005 and December 2014.

          -  All infants ≤12 months of age in Bogota, deceased between January 2005 and December
             2014 due to pertussis disease (primary diagnosis), based on death certificate
             information.

          -  All infants ≤12 months of age in Bogota, with ALRTI, between January 2005 and
             December 2014.

          -  All infants ≤12 months who have received primary pertussis vaccination in Bogota,
             between January 2005 and December 2014.

          -  All pregnant women who have received Boostrix as a part of the UMV program in Bogota,
             between March 2013 and December 2014.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Not applicable as since this retrospective database study will include all the available
        aggregated data of pertussis cases, pertussis related hospitalisations and deaths, ALRTI
        cases, primary pertussis vaccination coverage and Boostrix vaccination coverage.

        Exclusion Criteria:

        • Not applicable as since this retrospective database study will include all the available
        aggregated data of pertussis cases, pertussis related hospitalisations and deaths, ALRTI
        cases, primary pertussis vaccination coverage and Boostrix vaccination coverage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 1, 2017</lastchanged_date>
  <firstreceived_date>October 1, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Boostrix™</keyword>
  <keyword>Bagota</keyword>
  <keyword>maternal vaccination</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Mortality</keyword>
  <keyword>Morbidity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
